BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:efsubaglutide alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of efsubaglutide alfa\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07163650-277@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:efsubaglutide alfa: Phase 4 readout est. (NCT07163650)
DESCRIPTION:efsubaglutide alfa\, phase 4\, Obesity.\nStudy: Evaluating Anti
 -Obesity Medications 6 Months After Metabolic Surgery\nEstimated primary c
 ompletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/efsubaglutide-alfa#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07163650
URL:https://assetmemo.bio/drug/efsubaglutide-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693426-277@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:efsubaglutide alfa: Phase 1 readout est. (NCT07693426)
DESCRIPTION:efsubaglutide alfa\, phase 1\, Obesity.\nStudy: Phase Ib Study 
 of Efsubaglutide Alfa Injection in Obese Adolescents\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/efsubaglutide-alfa#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07693426
URL:https://assetmemo.bio/drug/efsubaglutide-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
